Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of Suzetrigine (VX-548) with Midazolam and Digoxin in Healthy Subjects
NCT05541471Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suzetrigine in pain, sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of Midazolam at Day 19, Maximum Observed Plasma Concentration of Digoxin at Day 19 and 4 more. Started Sep 2022; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05541471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541471.